RecruitingNot ApplicableNCT06382675

Clinical Performance of the New Plasma Filter PX2 in TPE Treatments

Clinical Performance of the New Plasma Filter PX2 in Combination With the multiFiltrate and multiFiltratePRO in TPE Treatments


Sponsor

Fresenius Medical Care Deutschland GmbH

Enrollment

46 participants

Start Date

Jul 18, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The plasma filter is applied for a single use in extracorporeal blood purification therapy. The intended purpose is the separation of plasma from blood by filtration, in conditions, which are associated with increased concentration of plasma components where a rapid depletion slows down or stops a pathogenic process. The investigation involves the collection of treatment data of the new Plasma Filter PX2 in combination with the multiFiltrate and multiFiltratePRO in therapeutic plasma exchange (TPE) treatments. The multiFiltrate and multiFiltratePRO are devices for extracorporeal blood purification treatments. No further control treatments will be investigated in this one arm design. The design is considered to be appropriate to reflect daily clinical practice and to contribute to empirical evidence of performance of the new Plasma Filter PX2. No specific treatment schedule is defined by the study protocol. The TPE treatment is performed with the plasma filter PX2 (investigational device) according to clinical practice established in each of the participating centers and are prescribed at the discretion of the treating physician. The participation in the study will have no influence on the treatment plan. The documentation of the treatment includes the therapy up to the tenth (10th) treatment.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Therapeutic Plasma Exchange (TPE) with the Plasma Filter PX2 for people with autoimmune diseases. The study is currently recruiting participants at 7 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICETherapeutic Plasma Exchange (TPE) with the Plasma Filter PX2

230 evaluable TPE treatments will be documented in the study (with an average of 5-7 TPE treatments per patient this corresponds to approximately 46 patients)


Locations(7)

Klinikum Aschaffenburg-Alzenau

Aschaffenburg, Bavaria, Germany

Klinikum der Ludwig-Maximilians-Universität München (LMU Klinikum)

Munich, Bavaria, Germany

Städtisches Klinikum Braunschweig

Braunschweig, Lower Saxony, Germany

St. Vincenz Kliniken

Paderborn, North Rhine-Westphalia, Germany

Charité-Universitätsmedizin Berlin

Berlin, State of Berlin, Germany

Universitätsklinikum Ulm

Ulm, Germany

Universitätsklinikum Würzburg

Würzburg, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06382675


Related Trials